|
| Press Releases |
|
 |
|
| Friday, October 3, 2025 |
|
|
Eisai Highlights Breadth of Oncology Research at ESMO 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of clinical research across its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2025, which is taking place in Berlin, Germany from October 17 to 21. more info >> |
|
| Monday, September 29, 2025 |
|
|
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI(R)" (generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the National Medical Products Administration (NMPA) in China. more info >> |
|
| Wednesday, September 24, 2025 |
|
|
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the Therapeutic Goods Administration (TGA) of Australia has approved the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI(R)" (brand name, generic name: lecanemab) for mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (AD) (collectively referred to as early AD) in adults who are either ApoEε4* non-carriers or heterozygous carriers. more info >> |
|
| Wednesday, September 17, 2025 |
|
|
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that etalanetug (development code: E2814), an investigational anti-MTBR (microtubule binding region) tau antibody, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). more info >> |
|
| Friday, September 12, 2025 |
|
|
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the release of a concept movie and new content on the dedicated website for its "New Answers to Dementia" campaign, designed to increase corporate awareness. more info >> |
|
| Monday, September 8, 2025 |
|
|
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house developed novel selective orexin 2 receptor agonist E2086 have been presented at the World Sleep 2025 congress, held in Singapore from September 5 to 10. more info >> |
|
| Thursday, September 4, 2025 |
|
|
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will deliver a total of 11 presentations, including clinical data on the selective orexin 2 receptor agonist (OX2R) E2086 and the latest findings on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO(R)) at the World Sleep Congress (World Sleep 2025) to be held in Singapore from September 5 to 10. more info >> |
|
| Wednesday, September 3, 2025 |
|
|
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai has initiated the rolling submission of the Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI(R)) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose after the FDA granted Fast Track Status. more info >> |
|
| Monday, September 1, 2025 |
|
|
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI(R) IQLIKTM, pronounced "I Click") for maintenance dosing. more info >> |
|
| Friday, August 29, 2025 |
|
|
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received orphan drug designation for anticancer agent the EZH2*1 inhibitor tazemetostat hydrobromide (genericname, product name "Tazverik(R) Tablets 200 mg", "tazemetostat") for unresectable INI1*2-negative epithelioid sarcoma that has progressed after chemotherapy, from the Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
DK88 Casino Officially Launches in Malaysia 
Feb 21, 2026 21:50 HKT/SGT
|
|
|
Graphene Manufacturing Group and Tickford Racing Unite to Push Performance Efficiency On and Off the Track
Feb 20, 2026 20:59 HKT/SGT
|
|
|
Full Convertible Bond Conversion Removes Overhang and Signals Valuation Reassessment for Shoucheng Holdings
Feb 20, 2026 20:32 JST
|
|
|
Investee Companies Take the National Stage: Shoucheng Holdings' 'Capital+Scenario+Industry Chain' Strategy Validated, Entering the Value Realization Phase
Feb 20, 2026 20:06 JST
|
|
|
Hong Kong designer labels shine at London Fashion Week
Feb 20, 2026 17:04 HKT/SGT
|
|
|
Spritzer EcoPark Champions Inclusive Experiences in Nature Through Meaningful Community Engagement
Feb 20, 2026 15:37 HKT/SGT
|
|
|
Shoucheng Holdings Draws Focus After Portfolio Companies Appear in Spring Festival Gala Robotics Showcase
Feb 20, 2026 15:29 HKT/SGT
|
|
|
Hitachi Rail Invests C$30 Million in New Canadian Headquarters
Feb 20, 2026 12:20 JST
|
|
|
The Capital Architect Behind the Gala Robots: Shoucheng Holdings (0697.HK) Enters a Milestone Year of Value Re-rating
Feb 20, 2026 09:11 HKT/SGT
|
|
|
Toyota Launches New RAV4 (PHEV) in Japan
Feb 19, 2026 19:25 JST
|
|
|
Osaka Hospital launches project to safely utilize generative AI for healthcare workforce improvements
Feb 19, 2026 12:12 JST
|
|
|
Asia's Protein Buyers Still Trail Global Best Practice -- But Momentum is Building, New ARE Benchmark Finds
Feb 19, 2026 11:02 HKT/SGT
|
|
|
CDAO Sydney 2026 Announces Two-Day, Co Located Event Series Uniting Australia's Senior Data & AI Leaders
Feb 18, 2026 17:17 HKT/SGT
|
|
|
India's Power Transition Creates Clear Utility Divide
Feb 18, 2026 16:00 HKT/SGT
|
|
|
MHI Machinery Systems Participates in Ramp Merging Support Demonstration Experiment for Autonomous Vehicles on the Tokyo Metropolitan Expressway
Feb 18, 2026 15:37 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
